系统综述与荟萃分析:功能性治愈对慢性乙型肝炎患者临床结局的影响
该系统综述与荟萃分析检索截至2021年5月的文献,纳入57项研究共258744例HBsAg阳性患者,其中63270例实现HBsAg清除。基于24项研究160598例患者的分析显示,HBsAg清除与肝细胞癌风险降低23%相关但未达统计学显著(RR=0.77;95%CI:0.38-1.57),HBsAg清除后肝硬化、失代偿、总体死亡和肝病相关死亡的合并比例较低,但所有结局存在显著异质性。
要点
- HBsAg清除与肝细胞癌风险降低23%相关,但未达统计学显著(RR=0.77;95%CI:0.38-1.57)。
- 治疗相关HBsAg清除后HCC合并比例0.94%,自发清除为0.45%,差异未达统计学显著。
- HBsAg清除后肝硬化、失代偿及死亡的合并比例低于未清除者,但异质性显著。
核心结论
- HBsAg清除与临床结局风险降低相关,但已发表研究的若干缺陷使HBsAg清除潜在获益的结论尚不能更明确。
研究设计与样本
- 系统综述与荟萃分析,检索PUBMED、Embase、Cochrane图书馆及已发表摘要至2021年5月。
- 纳入报告HBsAg清除、随访>1年且报告至少一项临床结局的成人慢性HBV感染研究。
- 共纳入57项研究,258744例HBsAg阳性患者,其中63270例实现HBsAg清除。
主要发现
- 基于24项研究160598例有无HBsAg清除患者,HBsAg清除与肝细胞癌风险降低23%相关但未达统计学显著(RR=0.77;95%CI:0.38-1.57)。
- 10项研究亚组荟萃分析中,治疗相关HBsAg清除后HCC合并比例0.94%,自发HBsAg清除为0.45%,差异未达统计学显著。
- HBsAg清除后HCC发生显著高于男性、存在基础肝硬化及有HCC家族史者。
- HBsAg清除与较低的新发肝硬化、肝失代偿、总体死亡和肝病相关死亡合并比例相关。
- 所有结局均存在显著异质性。
局限性
- 所有结局均存在显著异质性。
- 已发表研究存在若干缺陷,使HBsAg清除潜在获益的结论尚不能更明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although hepatitis B surface antigen (HBsAg) loss is considered the ideal therapeutic endpoint for the treatment of chronic hepatitis B virus (HBV) infection, its impact on clinical outcomes remains uncertain. AIM: To assess the impact of HBsAg loss on clinical outcomes following spontaneous and treatment-related HBsAg loss. METHODS: We searched PUBMED, Embase, the Cochrane library, and published abstracts through to May 2021 for studies that reported HBsAg loss, had >1 year of follow-up and reported at least one clinical outcome in adults with chronic HBV infection. RESULTS: We identified 57 studies (258 744 HBsAg-positive patients, 63 270 with HBsAg loss). Based on 24 studies including 160 598 patients with and without HBsAg loss, HBsAg loss was associated with a non-significant 23% relative risk reduction of developing hepatocellular carcinoma (HCC) compared to those who remained HBsAg-positive (RR = 0.77; 95% CI: 0.38-1.57). In subgroup meta-analysis of 10 studies, treatment-related HBsAg loss was associated with a non-significant higher pooled proportion of HCC (0.94%) compared to spontaneous HBsAg loss (0.45%). HCC development after HBsAg loss was significantly higher in males, those with underlying cirrhosis, and those with a family history of HCC. HBsAg loss was associated with lower pooled proportions of incident cirrhosis, hepatic decompensation, overall and liver-related mortality compared to no HBsAg loss. Substantial heterogeneity was noted across studies for all outcomes. CONCLUSION: HBsAg loss is associated with a reduced risk of clinical outcomes. However, several shortcomings in the published studies prevent a more definitive conclusion on the potential benefits of HBsAg loss.
引用
- Vittal A, Sharma D, Hu A, et al. Systematic review with meta-analysis: the impact of functional cure on clinical outcomes in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2021. PMID: 34850415. doi:10.1111/apt.16659
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。